Literature DB >> 9721655

Coagulin, a bacteriocin-like inhibitory substance produced by Bacillus coagulans I4.

B Hyronimus1, C Le Marrec, M C Urdaci.   

Abstract

A protease-sensitive antibacterial substance produced by Bacillus coagulans I4 strain, isolated from cattle faeces, was classified as a bacteriocin-like inhibitory substance and named coagulin. The inhibitory spectrum included B. coagulans and unrelated bacteria such as Enterococcus, Leuconostoc, Oenococcus, Listeria and Pediococcus. Coagulin was stable at 60 degrees C for 90 min, at a pH ranging from 4 to 8 and appeared to be unaffected by alpha-amylase, lipase or organic solvents (10% v/v). Coagulin exhibited a bactericidal and a bacteriolytic mode of action against indicator cells. The apparent molecular mass was estimated to be about 3-4 kDa by SDS-PAGE. The B. coagulans I4 strain harbours a plasmid, pI4, approximately 14 kb in size. Novobiocin curing experiments yielded two derivatives that no longer produced the bacteriocin-like inhibitory substance. Plasmid content of these two derivatives showed that one had lost pI4, whereas the second harboured a deleted form of this plasmid, thus suggesting a plasmid location for the genes for coagulin production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721655     DOI: 10.1046/j.1365-2672.1998.00466.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  32 in total

1.  Biochemical and genetic characterization of coagulin, a new antilisterial bacteriocin in the pediocin family of bacteriocins, produced by Bacillus coagulans I(4).

Authors:  C Le Marrec; B Hyronimus; P Bressollier; B Verneuil; M C Urdaci
Journal:  Appl Environ Microbiol       Date:  2000-12       Impact factor: 4.792

2.  Bacteriocin detection from whole bacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Thomas Hindré; Sandrine Didelot; Jean-Paul Le Pennec; Dominique Haras; Alain Dufour; Karine Vallée-Réhel
Journal:  Appl Environ Microbiol       Date:  2003-02       Impact factor: 4.792

3.  Bacteriocin diversity in Bacillus sphaericus.

Authors:  S Cetinkaya; O Osmanağaoğlu; C Cökmüş
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 4.  The continuing story of class IIa bacteriocins.

Authors:  Djamel Drider; Gunnar Fimland; Yann Héchard; Lynn M McMullen; Hervé Prévost
Journal:  Microbiol Mol Biol Rev       Date:  2006-06       Impact factor: 11.056

5.  The Effects of Probiotic Supplementation on Genetic and Metabolic Profiles in Patients with Gestational Diabetes Mellitus: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Mahtab Babadi; Ahmad Khorshidi; Esmat Aghadavood; Mansooreh Samimi; Elham Kavossian; Fereshteh Bahmani; Alireza Mafi; Rana Shafabakhsh; Mahbobeh Satari; Zatollah Asemi
Journal:  Probiotics Antimicrob Proteins       Date:  2019-12       Impact factor: 4.609

6.  Cloning and characterization of mersacidin like bacteriocin from Bacillus licheniformis MKU3 in Escherichia coli.

Authors:  Nagarajan Kayalvizhi; Neelamegam Rameshkumar; Paramasamy Gunasekaran
Journal:  J Food Sci Technol       Date:  2016-05-27       Impact factor: 2.701

Review 7.  Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrier.

Authors:  Na-Kyoung Lee; Won-Suck Kim; Hyun-Dong Paik
Journal:  Food Sci Biotechnol       Date:  2019-10-08       Impact factor: 2.391

8.  In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics.

Authors:  I V Pinchuk; P Bressollier; B Verneuil; B Fenet; I B Sorokulova; F Mégraud; M C Urdaci
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Administration of Bacillus coagulans in calves: recovery from faecal samples and evaluation of functional aspects of spores.

Authors:  Barbara Ripamonti; Alessandro Agazzi; Antonella Baldi; Claudia Balzaretti; Carla Bersani; Silvia Pirani; Raffaella Rebucci; Giovanni Savoini; Simone Stella; Alberta Stenico; Cinzia Domeneghini
Journal:  Vet Res Commun       Date:  2009-09-18       Impact factor: 2.459

10.  Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial.

Authors:  David R Mandel; Katy Eichas; Judith Holmes
Journal:  BMC Complement Altern Med       Date:  2010-01-12       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.